Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $90

Benzinga · 2d ago
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $85 to $90.